BioSpace News Archive

Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today announced that it will present data supporting its allogeneic pipeline program during the 60th American Society of Hematology (ASH) Annual Meeting & Exposition, taking place December 1-4 at the San Diego Convention Center.

The collaboration brings together deep clinical expertise with NuMedii’s Artificial Intelligence Drug Discovery technology, which will enable the discovery of novel targets and precision drug candidates for both acute and chronic forms of the disease.

Presentations will cover a wide range of blood diseases including multiple myeloma, lymphoma, chronic lymphocytic leukemia, acute myeloid leukemia, myelodysplastic syndromes and beta-thalassemia

New Orders, Production, and Employment Growing

for those living with a chronic gastrointestinal (GI) disorder like gastroesophageal reflux disease (GERD), that anticipation may be replaced by fear of unwanted symptoms.

Company to bring distribution in-house to further service brands like Dr. Kerklaan Therapeutics

Personalised polytherapeutic healthcare is the future. Leading this future is Hevilo Life Sciences with the introduction of Bespoke Personalised Healthcare (BPH) – an exclusive concierge service for individuals with the resources to facilitate greater control over their healthcare decisions.

With Canada once again debating public drug coverage, a new Conference Board of Canada report assesses different options for national pharmacare against key objectives identified earlier this year by senior health leaders.

NarrativeDx announced today that the US Patent Office has awarded to it a patent that covers the automated analysis of patient feedback, a cornerstone of consumerism strategies for many health systems.

Medela’s negative pressure wound therapy (NPWT) product line on a national basis.